The recent health guidelines classifying a BMI above 23 as obese for Indians have raised concerns about whether this single metric indiscriminately groups moderate weight gain with severe obesity. India's 2025 obesity definition does not treat obesity as a single label. It splits the diagnosis into two stages based on whether the extra weight has started to affect your body, not just the number on a scale.

The two stages matter because the same BMI can sit behind very different health pictures. Two people at a BMI of 27 may share a number but have entirely different metabolic realities. Staging shifts the clinical question from "how much does this person weigh?" to "what is that weight actually doing to them?" and adjusts how closely a doctor investigates and monitors the situation.

• India's 2025 definition lowers the obesity entry point for Asian Indians from a BMI of 25 to a BMI of 23.
• Stage 1 means weight is raised but blood markers, organ function and daily activity are all intact.
• Stage 2 requires abdominal obesity plus either a weight-related functional limit or at least one obesity-related disease.
• Abdominal obesity is defined as a waist of 90 cm or more in men, 80 cm or more in women, or a waist-to-height ratio above 0.5.
• This staging is a clinical professional consensus, not yet adopted as national government policy in India.

India's 2025 obesity definition, published by the India Obesity Commission, classifies an Asian Indian adult as having obesity at a BMI above 23 kg/m². It then sorts that diagnosis into two stages: Stage 1 is obesity without organ or functional impact, and Stage 2 is obesity that has begun to affect how the body works.

The framework comes from a 2025 expert consensus led by Misra and colleagues, developed through a five-round process involving 118 obesity clinicians across India. BMI on its own is a blunt tool: two people can share a BMI of 27 yet be in very different health. The staging asks whether excess weight is causing measurable harm before a clinical response is triggered, rather than treating every BMI over 23 the same way.

Only a clinician can place you in a stage after examining your blood markers, waist measurement and symptoms. This article explains what the categories mean, not where you personally sit.

Stage 1 obesity is a BMI above 23 kg/m² in a person whose blood sugar, blood pressure and lipids are all within a normal range, with no obesity-related disease and no weight-related limits on daily activity. It is obesity that has not yet caused measurable harm.

In practice, someone in Stage 1 can:

• Walk, bathe, dress and carry out routine tasks without weight-related breathlessness, palpitations or joint pain.
• Point to normal results across the blood markers that typically move early in metabolic disease: fasting glucose, HbA1c, lipids, blood pressure.
• Go about their daily life without limits traceable to body weight.

A large waistline alone does not push you out of Stage 1. Waist circumference and waist-to-height ratio may be measured at this stage, but the framework treats them as optional measures. A person with a waist above the Indian waist cut-offs can remain in Stage 1 as long as blood markers and daily function are intact.

Naming Stage 1 is about prevention. It flags raised risk early, before disease appears, so that lifestyle changes can be put in place while options are widest and any damage is still reversible. Treatment at this stage focuses on preventing progression rather than active medical intervention.

Stage 2 obesity requires three things together: a BMI above 23 kg/m², evidence of abdominal obesity, and either a weight-related limit on daily activity or at least one obesity-related disease.

Abdominal obesity is present when any one of the following applies:

• Waist of 90 cm or more in men
• Waist of 80 cm or more in women
• Waist-to-height ratio above 0.5

Once the BMI and waist criteria are both met, one further element must be present from either of the two categories below:

Functional limitation

This includes breathlessness, palpitations, poor exercise tolerance, or pain in weight-bearing joints during ordinary activities such as walking indoors, bathing, or dressing, when attributable to weight.

Obesity-related disease

One or more of the conditions listed below.

Obesity-related conditions that satisfy the disease arm of Stage 2:

• Type 2 diabetes
• Cardiovascular disease
• Obstructive sleep apnoea
• Non-alcoholic fatty liver disease
• Dyslipidaemia
• Hypertension
• Osteoarthritis of the lower spine and limbs
• Depression, anxiety or low self-esteem linked to weight
• Infertility
• Male hypogonadism
• Lower-limb oedema
• Polycystic ovary syndrome (PCOS)

Any single item from either arm is enough, provided the BMI and abdominal-obesity criteria are also met. In practice, a person moves from Stage 1 to Stage 2 when symptoms start to intrude on daily life, or when an obesity-related condition is diagnosed. Because much of India lacks easy access to advanced imaging, the framework relies on waist measurement and everyday symptoms rather than DEXA or specialist scans.

The previous Asian Indian 2009 consensus diagnosed obesity at a BMI of 25 or above. The 2025 update made three main changes:

1. The entry point dropped: Obesity now begins at a BMI above 23, the range the 2009 rules called merely "overweight." For Indian adults, this brings the clinical definition into line with the higher metabolic risk that research has consistently found at lower BMI values in this population.
2. Symptoms and disease became part of the diagnosis: In 2009, conditions such as diabetes or fatty liver were treated as consequences of obesity. In 2025 they are built into the definition itself, as the criteria that separate Stage 2 from Stage 1. This shifts the framework from a purely weight-based measure to one that reflects what weight is actually doing to the body.
3. New optional measures were added: These include a waist-to-height ratio above 0.5 and body-fat percentage thresholds: above 25.5% in men and above 38% in women. These allow clinicians to assess fat distribution more precisely where the tools are available.

What did not change: The waist cut-offs themselves (90 cm for men, 80 cm for women) stayed the same from 2009. The 2025 framework also overlays four BMI severity grades: 23 to 24.9, 25 to 27.5, 27.6 to 32.4, and 32.5 or above. These grades describe severity within a stage rather than changing which stage a person sits in.

As of 2026, the two-stage definition is a professional consensus rather than government policy. No major statutory body has formally adopted it as the national standard, and bodies such as ICMR and NAMS still reference the older WHO Asia-Pacific cut-offs. Globally, the Lancet Commission on clinical obesity uses a related "preclinical versus clinical" split that the two stages broadly echo, though the precise thresholds differ. The convergence across global frameworks suggests the staging logic is durable even if exact numbers shift further.

For you in practice, the staging is a clinical tool your doctor may already use to decide how closely to investigate your health and how actively to intervene, even though it is not yet in official public-health screening programmes. Understanding whether your weight sits alongside a normal metabolic profile or an emerging one is a more clinically useful question than whether you meet a particular BMI threshold.

Not sure which stage describes you?

The line between Stage 1 and Stage 2 turns on details a chart cannot see: your waist measurement, your blood markers, and whether weight has started to affect your daily life or your organs. A structured metabolic assessment with Voy's clinical team can measure where you sit and identify raised risk before it becomes disease. Understanding your stage is a starting point for action, not a final verdict.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.